Oren Berkowitz

Company: US Medical Director

Job title: Clinical Lead

Seminars:

Exploring Potential Impacts of COVID on Major Depressive Disorder Trial Data 9:30 am

The talk will present the results from CLEO phase 2 trial to assess the safety and efficacy ofbCLE-100 as an adjunctive treatment for Major Depressive Disorder (MDD) with inadequate response to previous antidepressants It will explore Potential Impacts of COVID-19 on Major Depressive Disorder Trial Data CLE-100 is an oral esketamine tablet formulated with abuse-deterrent…Read more

day: Conference Day One